Danaher (0R2B) Stock Overview
Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0R2B from our risk checks.
0R2B Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Danaher Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$185.10 |
| 52 Week High | US$244.50 |
| 52 Week Low | US$159.95 |
| Beta | 0.83 |
| 1 Month Change | 5.95% |
| 3 Month Change | -5.87% |
| 1 Year Change | -5.51% |
| 3 Year Change | -21.47% |
| 5 Year Change | -24.96% |
| Change since IPO | 143.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R2B | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0.8% | -1.2% | -0.6% |
| 1Y | -5.5% | 12.0% | 17.3% |
Return vs Industry: 0R2B underperformed the UK Life Sciences industry which returned 12% over the past year.
Return vs Market: 0R2B underperformed the UK Market which returned 17.3% over the past year.
Price Volatility
| 0R2B volatility | |
|---|---|
| 0R2B Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 11.8% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0R2B has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0R2B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 59,000 | Rainer Blair | www.danaher.com |
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.
Danaher Corporation Fundamentals Summary
| 0R2B fundamental statistics | |
|---|---|
| Market cap | US$132.10b |
| Earnings (TTM) | US$3.68b |
| Revenue (TTM) | US$24.78b |
Is 0R2B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R2B income statement (TTM) | |
|---|---|
| Revenue | US$24.78b |
| Cost of Revenue | US$10.16b |
| Gross Profit | US$14.62b |
| Other Expenses | US$10.94b |
| Earnings | US$3.68b |
Last Reported Earnings
Mar 27, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.19 |
| Gross Margin | 58.99% |
| Net Profit Margin | 14.83% |
| Debt/Equity Ratio | 34.9% |
How did 0R2B perform over the long term?
See historical performance and comparisonDividends
Does 0R2B pay a reliable dividends?
See 0R2B dividend history and benchmarks| Danaher dividend dates | |
|---|---|
| Ex Dividend Date | Jun 26 2026 |
| Dividend Pay Date | Jul 31 2026 |
| Days until Ex dividend | 20 days |
| Days until Dividend pay date | 55 days |
Does 0R2B pay a reliable dividends?
See 0R2B dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 17:47 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/27 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Danaher Corporation is covered by 45 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |